.Pharmacolibrary.Drugs.ATC.A.A10AE04 .Pharmacolibrary.Drugs.ATC.A.A10AE04| name: | InsulinGlargine |
| ATC code: | A10AE04 | route: | subcutaneous |
| n-compartments | 1 |
Insulin glargine is a long-acting insulin analog used to improve glycemic control in adults and children with diabetes mellitus. It is administered subcutaneously and provides a prolonged, relatively constant level of insulin activity. Insulin glargine is currently approved and widely used in clinical practice.
Pharmacokinetics in adult healthy volunteers and patients with diabetes (both type 1 and type 2); following subcutaneous administration.
Faggionato, E, et al., & Man, CD (2021). Modeling Between-Subject Variability in Subcutaneous Absorption of a Long-Acting Insulin Glargine 100 U/mL by a Nonlinear Mixed Effects Approach. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference 2021 4226–4229. DOI:10.1109/EMBC46164.2021.9629554 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34892156
Hurren, KM, & O'Neill, JL (2016). Pharmacodynamic and pharmacokinetic evaluation of insulin glargine U300 for the treatment of type 1 diabetes. Expert opinion on drug metabolism & toxicology 12(12) 1521–1526. DOI:10.1080/17425255.2016.1245722 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27710135
Rendell, M (2013). Insulin degludec: a long-acting modern insulin analogue with a predictable pharmacokinetic/pharmacodynamic profile. Drugs of today (Barcelona, Spain : 1998) 49(6) 387–397. DOI:10.1358/dot.2013.49.6.1976051 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23807942